+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07112196

Randomized Double-Blind Trial of Visugromab Versus Placebo for Treating Cancer-Associated Cachexia with Unintended Weight Loss

Led by CatalYm GmbH · Updated on 2026-11-02

518

Participants Needed

79

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well and safely a new drug called visugromab works in people with advanced cancers that cause unintended weight loss, known as cancer-associated cachexia. This trial aims to find out if visugromab helps participants regain weight, improve appetite, and increase physical activity compared to a placebo. The study is a randomized, double-blind phase 23 trial sponsored by CatalYm GmbH. Participants receive one of several doses of visugromab or a placebo through a drip into a vein once every four weeks. The study compares low, medium, and high doses of visugromab against a placebo over the course of treatment. The main treatment period focuses on evaluating changes in body weight and appetite at 12 weeks. During the study, participants visit the hospital or clinic every four weeks for infusions and checkups. Researchers monitor medical problems, physical activity, and weight changes. The primary outcomes measured are the change in body weight and appetite after 12 weeks of treatment. The study is expected to continue through 2030, with ongoing safety and efficacy assessments throughout the participation period.

CONDITIONS

Brief Title

Visugromab in Cachexia International Trial

Research Team

T

Trial Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here